Clopidogrel Tablet
Product Images NDC 31722-758

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 31722-758). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel-figure1 (Clopidogrel Figure1)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs)—Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole—on active metabolite AUC with mean values and 90% confidence intervals. The x-axis ranges from 0.4 to 1.4, illustrating variations in metabolite exposure when combined with each PPI.*

FDA Label Image

Clopidogrel-figure2 (Clopidogrel Figure2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, or stroke over 12 months of follow-up. The graph compares two groups: placebo (+ aspirin) and Clopidogrel Tablets (+ aspirin), with the Clopidogrel group showing a lower event rate throughout the period. A p-value of 0.00009 is indicated, demonstrating statistical significance.*

FDA Label Image

Clopidogrel-figure3 (Clopidogrel Figure3)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel to placebo across various subgroups. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes status, previous myocardial infarction, and previous stroke, with overall results included. The x-axis represents hazard ratio values from 0.3 to 1.4, highlighting favor toward Clopidogrel or placebo.*

FDA Label Image

Clopidogrel-figure4 (Clopidogrel Figure4)

A line graph comparing the percentage of deaths before first discharge over 28 days between placebo and clopidogrel treatment groups. The x-axis represents days since randomization, and the y-axis shows the percent dead. The graph shows slightly lower death rates for the clopidogrel group compared to placebo, with values and a noted 7% proportional risk reduction (p=0.03).*

FDA Label Image

Clopidogrel-figure5 (Clopidogrel Figure5)

A Kaplan-Meier curve comparing the percentage of patients experiencing death, re-infarction, or stroke before first discharge over 28 days between a placebo group and a clopidogrel group. The Y-axis shows percentage with event, and the X-axis shows days since randomization. The graph notes 10.1% event rate for placebo and 9.2% for clopidogrel, indicating a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Clopidogrel-figure6 (Clopidogrel Figure6)

A forest plot chart showing odds ratios with 99% confidence intervals comparing outcomes between Clopidogrel and placebo groups across subgroups such as gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot visually indicates whether outcomes favor Clopidogrel or placebo for each subgroup.*

FDA Label Image

Clopidogrel-figure7 (Clopidogrel Figure7)

A line graph showing the cumulative event rate percentage of fatal or non-fatal vascular events over a 36-month follow-up period, comparing Aspirin with Clopidogrel Tablets. The graph indicates a statistical difference with a P-value of 0.045.*

FDA Label Image

Clopidogrel-figure8 (Clopidogrel Figure8)

A forest plot comparing the hazard ratios with 95% confidence intervals for outcomes related to stroke, myocardial infarction (MI), and peripheral artery disease (PAD) between Clopidogrel and Aspirin. The chart shows the number and percentage of events for each drug and indicates which drug is favored based on the relative hazard ratios, including an overall comparison.*

FDA Label Image

Clopidogrel-structure (Clopidogrel Structure)

Chemical structure of clopidogrel sulfate, showing its molecular arrangement including chloro, methyl ester, thiophene, and aromatic rings as part of its active ingredient composition.*

FDA Label Image

Clopidogrel-tablets-300mg-30s-container (Clopidogrel Tablets 300mg 30s Container)

Clopidogrel Tablets USP 300 mg oral tablets label from Camber Pharmaceuticals, Inc. The package contains 30 tablets and is identified with NDC 31722-759-30. The label includes storage instructions, a pharmacist dispensing note, a contact number, and manufacturer information for Annora Pharma Pvt. Ltd. in India.*

FDA Label Image

Clopidogrel-tablets-75mg-30s-container (Clopidogrel Tablets 75mg 30s Container)

Clopidogrel Tablets USP 75 mg oral tablet label by Camber Pharmaceuticals, Inc. The label states the product strength as 75 mg, packaging of 30 tablets, and includes storage instructions, medication guide info, contact number, manufacturing details, and barcode. It specifies the tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.